Google
BCRX 株価分析 — Biocryst Pharmaceuticals Inc (Healthcare >> Drug Manufacturers - Specialty & Generic)
BCRX に関するよくある質問
BCRXのPER（株価収益率）は？
Biocryst Pharmaceuticals Inc（BCRX）は現在PER 8.90倍で取引されています。
BCRXのROE（自己資本利益率）は？
Biocryst Pharmaceuticals IncのROEは82.69%です。
BCRXの配当利回りは？
Biocryst Pharmaceuticals Incの配当利回りは0.00%です。
BCRXの品質スコア（Quality Score）は？
当社のAIはBCRXの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BCRXは今が買い時ですか？
当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BCRXはどのセクターに属しますか？
Biocryst Pharmaceuticals IncはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）
BCRX AI Analysis Summary
Our AI summary for BCRX: Biocryst Pharmaceuticals Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 8.90, ROE of 82.69%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 8.98
Price
-0.26
(-2.81%)
Day Change
|
|
|---|
BCRX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
118
|
| Magic Formula Rank by ROE |
118
|
| Magic Formula Rank by ROIC |
125
|
| Price | 8.98 |
| PBV / Sector |
-4.24 / 3.22
|
| Earning Per Share | -1.75 |
| PE / Sector |
8.90 / 29.79
GREAT
|
| PEG or PE/Growth / Sector |
-0.06 / 0.13
|
| Average 1M Daily Value |
36.89 M
GREAT
|
| Average 1W Daily Value |
26.97 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:32 |
| Symbol | BCRX |
| Name | BIOCRYST PHARMACEUTICALS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 254.16 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,348.46 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4505 Emperor Boulevard, Durham, NC, United States, 27703
Phone: 919 859 1302
Website: https://www.biocryst.com
Employees: 435
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
